Human Biclonics® for Superior Clinical Efficacy

Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.


Biclonics® retain the format of antibodies that are produced naturally by the immune system, retaining their favorable attributes including stability and predictability during manufacturing and long half-life and low immunogenicity during treatment of patients. Learn more about our technology


Our pipeline comprises Biclonics® for solid and hematological tumors that target combinations of growth factor receptors and immunomodulatory molecules. See what's in our pipeline


We make our technologies available in partnerships based on promising target combinations. Please contact us for further information.


UTRECHT, The Netherlands and VILLEJUIF, France, Jan. 04, 2016 (GLOBE NEWSWIRE) — Merus B.V., a clinical-stage immuno-oncology company developing...
Novartis Oncology’s Former Global Head of Business Development and Licensing Joins Immuno-oncology Biotech Company UTRECHT, The Netherlands, Dec. 16,...
Court Further Rules That Regeneron Engaged in Affirmative Egregious Misconduct UTRECHT, The Netherlands, Nov. 3, 2015 (GLOBE NEWSWIRE) — Merus B.V.,...